Navigation Links
AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
Date:11/1/2010

ALISO VIEJO, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced a management conference call to discuss the approval of NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) by the U.S. Food and Drug Administration (FDA).  The call is scheduled for today, Monday November 1, 2010 at 5:15 a.m. Pacific time / 8:15 a.m. Eastern time.  

The live call can be accessed by dialing (877) 558-3407 for domestic callers and (706) 679-1941 for international callers.  The conference ID number is 22130601.  A webcast of the live call can be accessed by visiting AVANIR's corporate website at www.avanir.com.  To view the live webcast, please go to AVANIR's website prior to the start of the call to register, download, and install the necessary software.

An archived copy of the webcast will be available on AVANIR's website for 30 days, and a telephone replay will be available through November 6, 2010, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 22130601.  

About NUEDEXTA

NUEDEXTA™ is the first and only FDA-approved treatment for pseudobulbar affect (PBA).  NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations.  NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.  

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA).  PBA occurs secondary to a variety of otherwise unrelated neurologi
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... , May 16, 2013  HeartWare International, Inc. (NASDAQ: ... of less invasive, miniaturized circulatory support technologies that are revolutionizing ... Doug Godshall is scheduled to present ... EDT on Monday, May 20, 2013.  The conference is being ... A live webcast of the Company,s presentation at ...
(Date:5/16/2013)... , May 16, 2013  Amgen (NASDAQ: AMGN ... on Tuesday, May 21, 2013, at the Sheraton New York ... beginning at 10:00 a.m. Eastern Daylight Time. Joseph ... Research and Development at Amgen, will present at the conference. ... Events Calendar on Amgen,s website, www.amgen.com , under Investors. ...
(Date:5/16/2013)... -- OrthoView PSL will allow individual surgeons ... widely-used OrthoView digital templating software via the Cloud and ... started. OrthoView, the leading independent provider of ... dedicated to enabling orthopaedic surgeons in hospitals and private ... film is unavailable. Over 5,000 orthopaedic surgeons in the ...
Breaking Medicine Technology:HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2
... Medical, Inc. (OTCBB: AEMD), the pioneer in developing ... cancer, announced today the introduction of HER2osome™, a ... of HER2+ breast cancer, which is characterized by ... over-expression of HER2 protein.  Breast cancer represents the ...
... Sept. 21, 2011 Reportlinker.com announces that a ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619264/Generic-Drugs-The-Global-Market-Focus-on-the-Americas.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... examination of the strategies employed by companies specializing ...
Cached Medicine Technology:Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 2Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 3Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 4Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 5Generic Drugs: The Global Market: Focus on the Americas 2Generic Drugs: The Global Market: Focus on the Americas 3Generic Drugs: The Global Market: Focus on the Americas 4Generic Drugs: The Global Market: Focus on the Americas 5Generic Drugs: The Global Market: Focus on the Americas 6Generic Drugs: The Global Market: Focus on the Americas 7Generic Drugs: The Global Market: Focus on the Americas 8Generic Drugs: The Global Market: Focus on the Americas 9Generic Drugs: The Global Market: Focus on the Americas 10
(Date:5/18/2013)... Minn. -- Regular consumption of coffee is associated ... (PSC), an autoimmune liver disease, Mayo Clinic research ... Digestive Disease Week 2013 conference in Orlando, Fla. ... the bile ducts that results in inflammation and ... the liver, liver failure and biliary cancer. , ...
(Date:5/18/2013)... May 18, 2013 Today, Zane ... insurance agents’ role in Marketplaces . Zane Benefits, ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to ... Human Services (HHS) recently released a much-anticipated statement ...
(Date:5/18/2013)... 2013 The “World Healthcare IT Market: ... the major market drivers, restraints, and opportunities in North ... Browse , 89 market data ... on "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... reports. , The global healthcare IT market is expected ...
(Date:5/18/2013)... 2013 As metal-on-metal hip implant ... country, Bernstein Liebhard LLP notes that a new study ... tissue damage before they experience any pain from a ... Daily will appear in the Journal of Bone & ... screens of their hips. The researchers found tissue ...
(Date:5/18/2013)... The “Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, ... Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive ... major market drivers, restraints, and opportunities in North America, ... , 147 market data tables ... 318 pagesand in-depth TOC of “Sleep Apnea ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... at the Queensland Institute of Medical Research (QIMR) and the ... and successfully treated it by performing an experimental stem cell ... and out of hospital Katie Pulling had almost given up ... hearing the doctors say, ,We don,t know what is wrong, ...
... the forefront of HIV prevention research will be taking center ... L. Lawrence Convention Center in Pittsburgh May 22-25. M2010 ... community advocates and experts in global health who are working ... of the world. Nearly 1,000 participants from 47 countries will ...
... ... to look for. Flexible Assembly Systems uncovers the great torque screwdriver mystery with its very ... ... you don’t know what to look for. A torque screwdriver comes in many different ...
... controlled severe disease using less medication , MONDAY, May ... be a mouse click away, Dutch researchers report. , ... program maintained long-term control of severe asthma but needed ... do so, the study found. , "We know that ...
... researchers say , MONDAY, May 17 (HealthDay News) -- ... organophosphate pesticides, commonly found on berries, celery and other ... (ADHD) in children. , At this point, though, there ... ADHD, stated the authors of a paper appearing in ...
... Fighting ... takes is one look at the brand and the name to get an instant smile and chuckle. ... , ... Drink (FCE) is a concept that was born on the cusp of the energy drink boom that ...
Cached Medicine News:Health News:Australian researchers identify a new disease 2Health News:Press briefings at International Microbicides Conference May 22-25 2Health News:Press briefings at International Microbicides Conference May 22-25 3Health News:Press briefings at International Microbicides Conference May 22-25 4Health News:Press briefings at International Microbicides Conference May 22-25 5Health News:Flexible Assembly Systems Announces Torque Screwdriver Application Guide 2Health News:Web-Based Program Can Boost Asthma Care 2Health News:Pesticides on Produce Tied to ADHD in Children 2Health News:Pesticides on Produce Tied to ADHD in Children 3Health News:Unique Marketing Approach to the Energy Drink Market Brings Explosive Response 2
... Our Buffered Wright-Giemsa Stain is ... contains the fixative, buffer, and ... staining of blood smears. It ... bottle for ease of use ...
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCP). Storage temp: 15 - 30 C. Linearity: 0.5 - 8.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 250 number of tests....
Medicine Products: